Modified Citrus Pectin (MCP), a low-molecular-weight, low-esterification derivative of natural citrus pectin, has emerged as a groundbreaking anti-cancer therapeutic. Unlike dietary pectin-which primarily acts as a soluble fiber in the colon-MCP exhibits systemic bioavailability, enabling direct interactions with cancer cells and immune modulation. Its most significant mechanism involves antagonizing galectin-3 (Gal-3), a β-galactoside-binding lectin overexpressed in aggressive cancers, making MCP a promising candidate for cancer prevention and treatment.
Zhejiang Gold Kropn Biotechnology Co., Ltd. is a national high-tech enterprise integrating scientific research, production, and sales. In collaboration with leading academic institutions such as Zhejiang University, Fudan University, Tianjin University, and Xinxiang Medical University in Henan, the company actively conducts research on a series of health food products featuring modified citrus pectin (MCP). Its products are exported to numerous countries and regions worldwide.
Modified citrus pectin (MCP) is recognized as a safe food ingredient by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), with its Acceptable Daily Intake (ADI) classified as "not specified," indicating its high safety profile.
The company operates a 100,000-grade GMP-certified production facility, utilizing imported lemon peels as raw material and employing advanced enzymatic hydrolysis technology to extract high-purity MCP. Every step of the process-from raw material selection to production-is strictly controlled. The company adheres to natural ingredients and clean production methods to ensure product safety and superior quality.
Gal-3 plays a pivotal role in cancer progression: it promotes metastasis by facilitating cancer cell adhesion to endothelia, inducing angiogenesis, and suppressing apoptosis. MCP's RG-I domain, rich in terminal galactose residues, binds with high affinity to Gal-3's carbohydrate recognition domain (CRD), inhibiting its oncogenic functions. Preclinical studies demonstrate that MCP:
Reduces metastasis by disrupting cancer cell homotypic/heterotypic aggregation and endothelial adhesion.
Induces anoikis (detachment-induced apoptosis) in circulating cancer cells.
Sensitizes tumors to chemotherapy (e.g., enhancing dexamethasone-induced apoptosis in multiple myeloma).
Modulates immunity by activating NK cells, T-cells, and macrophages while countering Gal-3-mediated T-cell suppression.
Structurally, MCP's efficacy in cancer therapy hinges on its molecular weight (5–20 kDa) and degree of esterification (<10%), enabling passive absorption and Gal-3 targeting. Neutral galactan-rich fragments (e.g., MCP-M) exhibit the strongest Gal-3 inhibition, directly impacting cancer cell survival. Animal models confirm MCP's ability to suppress liver, lung, and prostate metastases, highlighting its potential as a multi-target anti-cancer agent.
Clinical trials, though limited, show promise for MCP in cancer management. A Phase II study in prostate cancer patients reported prolonged PSA doubling time after MCP supplementation. Another trial in advanced solid tumors noted disease stabilization and improved quality of life in 22.5% of patients, underscoring MCP's role in cancer care. Ongoing Phase III trials (e.g., NCT01841828) aim to validate these findings and explore MCP's broader applications in cancer therapy.
Conclusion: MCP's multi-target action against Gal-3 positions it as a versatile adjuvant in cancer therapy. Future work must optimize its structure for enhanced bioavailability and evaluate combinatorial regimens with conventional anti-cancer treatments to maximize clinical outcomes. By targeting Gal-3 and modulating the tumor microenvironment, MCP offers a novel approach to combating cancer progression and improving patient survival.